If you want a large pharmaceutical company to invent a new drug, your best bet is probably AstraZeneca. But if you have a medicine you’d like to get to market — and you want to see it generate revenue — you might be better off with Pfizer.
That’s the message from the 12th edition of the Pharmaceutical Innovation and Invention Index, produced by the consultancy Idea Pharma, which was released Thursday at the STAT Breakthrough Summit.
Every year, Idea ranks the largest pharmaceutical companies based on two measures: what it calls invention, which is basically how good they are at coming up with new medicines, and innovation, which the firm defines as the ability to run clinical trials, deal with regulators, handle manufacturing, and market the new medicine. The rankings themselves are interesting for those who follow pharma, and the data behind them give some key insights into how the industry as a whole is doing and what it takes to bring a new medicine to market.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect